Healthcare Analysts, along with Dr. Wharton, a cardiologist from North Shore University Hospital, discuss the market opportunity in treating Hypertrophic Cardiomyopathy (HCM), with a focus on Camzyos (Mavacamten) by Bristol Myers Squibb (BMY), as well as the Aficamten program by Cytokinetics (CYTK) and its Phase 3 Trial (SEQUOIA) on an Analyst/Industry conference call to be held on November 20 at 1 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- 2seventy Bio downgraded to Neutral at Wedbush after FDA panel announcement
- Bristol Myers Squibb (NYSE:BMY) Falls after FDA Delays Action on Cancer Therapy
- Bristol Myers, 2seventy Bio provide update on FDA review of Abecma application
- Bayer news ‘boding poorly’ for Bristol Myers’ Factor XIa trial, says Barclays
- Needham healthcare analysts hold an analyst/industry conference call